《大行报告》瑞银升药明巨诺-B(02126.HK)评级至「买入」 目标价下调至42.2元
瑞银发表报告指,药明巨诺-B(02126.HK)去年录亏损16.64亿元人民币,较2019年的亏损6.33亿元人民币有所扩大,主要是由於优先股及认股证公平值变动、研发开支增加,及基於股份的薪酬提高。若撇除非持续项目的影响,去年经调整亏损3.04亿元人民币,对比2019年为亏损1.89亿元人民币。
该行表示,药明巨诺-B(02126.HK)股价已较2月底的高位回调约40%,相信已完全反映来自零风险收益率(risk-free rate)上升的波动,及投资者对早期生物制药企业的担心。
瑞银上调药明巨诺股份评级,由「中性」升至「买入」,目标价由51.7元下调至42.2元,相信集团目前的风险回报吸引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.